Remove Drugs Remove Pharma Companies Remove Pharma Production Remove Regulation
article thumbnail

Is License Compulsory For Starting Pharmaceutical Business In India?

Fossil Remedies

When you launch a PCD pharma company , you have to do several preparations. In a pharma business, you have a distribution network like a pharma manufacturing company, pharma marketing company, C&F agents, wholesalers/distributors/stockiest, retailers, and pharmacies. Wholesale Drug License.

article thumbnail

Another reason change is needed at FDA? Fair balance

World of DTC Marketing

Pharma TV ads drive people online to search for more information. Safety pages on Pharma product websites continue to have high utility. Only requirement in TV ads should be for “boxed” products. Prescription drugs are not the same as items found in a grocery store. ” They go online to learn more.

Doctors 165
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Russia’s focus on domestic pharma production could shield it from sanctions’ effects

Pharmaceutical Technology

Compared with other emerging pharmaceutical markets (such as India and China, covered in previous Emerging Market Outsourcing Reports), Russian facilities lack many US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals, meaning Russian manufacturing is more focused on the domestic market.

article thumbnail

Brazil: untapped market for big pharma manufacturing

Pharmaceutical Technology

SUS provides full, free and universal access to healthcare for the country's entire population (215 million), which spends around 10% of its gross domestic product (GDP) on healthcare. Only a limited number of international pharma companies, however, operate manufacturing sites in the country.

article thumbnail

Brexit fallout continues with batch testing concerns

Pharmaceutical Technology

In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.

Medicine 290